1. SPEEDS: A portable serological testing platform for rapid electrochemical detection of SARS-CoV-2 antibodies
- Author
-
Ran Peng, Xinyu Liu, Yueyue Pan, James M. Rini, Zhen Qin, and Zhijie Li
- Subjects
Immunity screening ,Biomedical Engineering ,Biophysics ,Biosensing Techniques ,02 engineering and technology ,Antibodies, Viral ,Sensitivity and Specificity ,Point-of-care diagnosis ,Article ,Immunoglobulin G ,Virus ,COVID-19 Serological Testing ,Herd immunity ,Serology ,03 medical and health sciences ,Immune system ,Serological test ,Electrochemistry ,Humans ,Medicine ,Pandemics ,030304 developmental biology ,Immunoassay ,0303 health sciences ,biology ,SARS-CoV-2 ,business.industry ,COVID-19 ,General Medicine ,021001 nanoscience & nanotechnology ,Virology ,3. Good health ,Vaccination ,Immunoglobulin M ,Spike Glycoprotein, Coronavirus ,Electrochemical biosensing ,biology.protein ,Antibody ,0210 nano-technology ,business ,Biotechnology - Abstract
The COVID-19 pandemic has resulted in a worldwide health crisis. Rapid diagnosis, new therapeutics and effective vaccines will all be required to stop the spread of COVID-19. Quantitative evaluation of serum antibody levels against the SARS-CoV-2 virus provides a means of monitoring a patient’s immune response to a natural viral infection or vaccination, as well as evidence of a prior infection. In this paper, a portable and low-cost electrochemical immunosensor is developed for the rapid and accurate quantification of SARS-CoV-2 serum antibodies. The immunosensor is capable of quantifying the concentrations of immunoglobulin G (IgG) and immunoglobulin M (IgM) antibodies against the SARS-CoV-2 spike protein in human serum. For IgG and IgM, it provides measurements in the range of 10.1 ng/mL − 60 µg/mL and 1.64 ng/mL − 50 µg/mL, respectively, and both antibodies can be assayed in 13 min. We also developed device stabilization and storage strategies to achieve stable performance of the immunosensor within 24-week storage at room temperature. We evaluated the performance of the immunosensor using COVID-19 patient serum samples collected at different time points after symptom onset. The rapid and sensitive detection of IgG and IgM provided by our immunosensor fulfills the need of rapid COVID-19 serology testing for both point-of-care diagnosis and population immunity screening.
- Published
- 2022